JNJ

190.31

-0.15%↓

ABT

127.15

+0.3%↑

MDT

94.09

+0.34%↑

VEEV

295.48

+0.77%↑

A

146.74

-0.99%↓

JNJ

190.31

-0.15%↓

ABT

127.15

+0.3%↑

MDT

94.09

+0.34%↑

VEEV

295.48

+0.77%↑

A

146.74

-0.99%↓

JNJ

190.31

-0.15%↓

ABT

127.15

+0.3%↑

MDT

94.09

+0.34%↑

VEEV

295.48

+0.77%↑

A

146.74

-0.99%↓

JNJ

190.31

-0.15%↓

ABT

127.15

+0.3%↑

MDT

94.09

+0.34%↑

VEEV

295.48

+0.77%↑

A

146.74

-0.99%↓

JNJ

190.31

-0.15%↓

ABT

127.15

+0.3%↑

MDT

94.09

+0.34%↑

VEEV

295.48

+0.77%↑

A

146.74

-0.99%↓

Search

Arcus Biosciences Inc

Cerrado

SectorSalud

18.56 7.35

Resumen

Variación precio

24h

Actual

Mínimo

17.45

Máximo

18.78

Métricas clave

By Trading Economics

Ventas

132M

160M

Empleados

627

EBITDA

126M

4M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 meses

+86.77% upside

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

882M

1.9B

Apertura anterior

11.21

Cierre anterior

18.56

Noticias sobre sentimiento de mercado

By Acuity

34%

66%

92 / 373 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Neutral Evidence

Arcus Biosciences Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

27 oct 2025, 23:32 UTC

Adquisiciones, fusiones, absorciones

CSL Delays Flu-Vaccine Spinoff, Cuts Guidance As U.S. Vaccination Rates Decline

27 oct 2025, 23:00 UTC

Adquisiciones, fusiones, absorciones

Australia's AUB Opens Books to EQT After Receiving $3.44 Billion Takeover Offer

27 oct 2025, 21:42 UTC

Ganancias

Waste Management 3Q Revenue Climbs, Sees Fiscal Year Revenue at Low End of Prior View

27 oct 2025, 23:43 UTC

Charlas de Mercado

Nikkei May Rise on Easing U.S.-China Trade Tensions -- Market Talk

27 oct 2025, 23:42 UTC

Charlas de Mercado

Gold Rises on Likely Technical Recovery -- Market Talk

27 oct 2025, 23:37 UTC

Charlas de Mercado

Investors May Cheer CSL's Decision to Delay Seqirus Spinoff -- Market Talk

27 oct 2025, 23:00 UTC

Ganancias

The Good Vibes Are Back on Wall Street -- WSJ

27 oct 2025, 22:45 UTC

Adquisiciones, fusiones, absorciones

Australia's AUB Opens Books to EQT After Receiving $3.44B Takeover Offer

27 oct 2025, 22:06 UTC

Charlas de Mercado
Ganancias

Nucor Expects Weaker Steel Market in 4Q -- Market Talk

27 oct 2025, 22:05 UTC

Ganancias

China Southern Airlines: Continued Improvements in Business Environment Supported Results >1055.HK

27 oct 2025, 22:04 UTC

Ganancias

Cadence Reports Solid Earnings. The Stock Is Falling. -- Barrons.com

27 oct 2025, 22:04 UTC

Ganancias

China Southern Airlines 3Q Net CNY3.84B, Up 20.3% on Year >1055.HK

27 oct 2025, 22:03 UTC

Ganancias

China Southern Airlines 3Q Rev CNY51.37B, Up 3.0% on Year >1055.HK

27 oct 2025, 21:27 UTC

Ganancias

Waste Management 3Q Rev Climbs, Sees FY Rev at Low End of Prior View

27 oct 2025, 21:19 UTC

Ganancias

Cadence Reports Solid Earnings. The Stock Is Falling. -- Barrons.com

27 oct 2025, 20:50 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Health Care Roundup: Market Talk

27 oct 2025, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

27 oct 2025, 20:37 UTC

Ganancias

Waste Management: Decrease From Prior Rev Expectations Is Primarily Related to Further Decline in Recycled Commodity Pricing, Modestly Lower Rev Expectations From Healthcare Solutions >WM

27 oct 2025, 20:37 UTC

Ganancias

Waste Management: 2025 Free Cash Flow Guidance Remains Between $2.8B and $2.9B >WM

27 oct 2025, 20:37 UTC

Ganancias

Waste Management: 2025 Total Co Rev Is Now Expected Approximately $25.275B >WM

27 oct 2025, 20:37 UTC

Ganancias

Waste Management: Affirming 2025 Adjusted Operating EBITDA Guidance Between $7.475B and $7.625B >WM

27 oct 2025, 20:31 UTC

Ganancias

Nucor Sees 4Q Earnings Lower Than 3Q

27 oct 2025, 20:30 UTC

Ganancias

Nucor 3Q Steel Mills Total Shipments 6.43M Tons >NUE

27 oct 2025, 20:30 UTC

Ganancias

Nucor 3Q EPS $2.63 >NUE

27 oct 2025, 20:30 UTC

Ganancias

Nucor 3Q Net $607M >NUE

27 oct 2025, 20:30 UTC

Ganancias

Nucor 3Q Sales $8.52B >NUE

27 oct 2025, 20:30 UTC

Ganancias

Nucor 3Q Total Tons Shipped to Outside Customers Down 1% >NUE

27 oct 2025, 20:30 UTC

Ganancias

Waste Management 3Q Adj EPS $1.98 >WM

27 oct 2025, 20:30 UTC

Ganancias

Waste Management 3Q Rev $6.44B >WM

27 oct 2025, 20:30 UTC

Ganancias

Waste Management 3Q Net $603M >WM

Comparación entre iguales

Cambio de precio

Arcus Biosciences Inc Esperado

Precio Objetivo

By TipRanks

86.77% repunte

Estimación a 12 meses

Media 32.33 USD  86.77%

Máximo 54 USD

Mínimo 14 USD

De acuerdo con 12 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Arcus Biosciences Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

12 ratings

11

Comprar

1

Mantener

0

Vender

Puntuación técnica

By Trading Central

8.01 / 8.75Soporte y Resistencia

Corto Plazo

Neutral Evidence

Medio plazo

Neutral Evidence

Largo Plazo

Weak Bearish Evidence

Sentimiento

By Acuity

92 / 373 Clasificación en Salud

Noticias sobre sentimiento de mercado

Coyuntura alcista

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Arcus Biosciences Inc

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.
help-icon Live chat